RT @TheLancet: Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of majo
Tweet Content
Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj
Links
DEFINE_ME
https://hubs.li/H0zws6H0
Show on Archive Page
On
Display in Search Results
On